API | censavudine

censavudine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Censavudine (INN) (BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023. ^Wikipedia

Chemistry

SMILES: C#C[C@@]1(CO)C=C[C@H](n2cc(C)c(=O)[nH]c2=O)O1
InChIKey: OSYWBJSVKUFFSU-SKDRFNHKSA-N
Mol. Mass: 248.24
ALogP: -0.71 Partition coefficient
ChEMBL Molecule:
censavudine

More Chemistry

Pharmacology

Mechanisms of Action:
- Reverse transcriptase/RNaseH (Human immunodeficiency virus 1) ^UniProt
- Reverse transcriptase (Human immunodeficiency virus 2) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

HIV Infections (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue